Cover Image
市場調查報告書

低血糖症 : 開發平台分析

Hypoglycemia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229785
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
低血糖症 : 開發平台分析 Hypoglycemia - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 80 Pages
簡介

低血糖症發生於血液中的葡萄糖過低時。葡萄糖是人體重要的能源來源。低血糖症雖然發病相當突然,但可輕易藉由消費高血糖值血液來迅速控制。低血糖的症狀有空腹感和顫抖、神經質、冷汗、暈眩/朦朧狀態、睡意、混亂、睡眠障礙、不安感、四肢無力感等。睡眠中的低血糖徵兆,則指怪聲和惡夢,發汗造成睡衣和床單潮濕,起床時易感到疲勞和焦躁及困惑等。同時更會出現各種血糖症治療藥的副作用。飲食不規則進食不足,身體活動增加,攝取酒精飲料等理由也會造成低血糖症,或注射或服用促使胰島素增加之藥物的人們身上也一樣會發生。

本報告提供全球各國治療低血糖症用的開發中產品開發情形相關分析、彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)進展狀況)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

低血糖症概要

治療藥的開發

  • 低血糖症開發中產品:概要
  • 低血糖症開發中產品:比較分析

各企業開發中的低血糖症治療藥

大學/研究機關研究中的低血糖症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

低血糖症治療藥:開發中的產品一覽(各企業)

低血糖症治療藥:研究中的產品一覽(大學/研究機關)

低血糖症開發治療藥的企業

  • Biodel Inc.
  • Eli Lilly and Company
  • Heptares Therapeutics Limited
  • Novartis AG
  • SkyePharma Plc
  • USV Limited
  • XERIS Pharmaceuticals, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S

低血糖症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • 低血糖症生技藥品
  • glucagon
  • pasireotide
  • GLP-1 受體拮抗劑
  • terbutaline sulphate
  • XOMA-358
  • ZP-4207

低血糖症治療藥:最新的藥物簡介

低血糖症治療藥:開發暫停的產品

低血糖症治療藥:開發中止的產品

低血糖症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9565IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 6, 5, 3 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypoglycemia - Overview
    • Hypoglycemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hypoglycemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypoglycemia - Companies Involved in Therapeutics Development
    • Adocia SAS
    • Arecor Ltd
    • Eiger BioPharmaceuticals Inc
    • Eli Lilly and Company
    • Heptares Therapeutics Ltd
    • LATITUDE Pharmaceuticals Inc
    • Novartis AG
    • Therakind Ltd
    • USV Pvt Ltd
    • Vectura Group Plc
    • XERIS Pharmaceuticals Inc
    • XOMA Corp
    • Zealand Pharma AS
    • Zucara Therapeutics Inc
  • Hypoglycemia - Drug Profiles
    • (glucagon + GLP-1) - Drug Profile
    • (insulin human + pramlintide) - Drug Profile
    • dasiglucagon - Drug Profile
    • Drug for Hypoglycemia - Drug Profile
    • exendin-(9-39) - Drug Profile
    • glucagon - Drug Profile
    • glucagon - Drug Profile
    • glucagon - Drug Profile
    • glucagon - Drug Profile
    • glucagon biosimilar - Drug Profile
    • LY-3143753 - Drug Profile
    • LY-3185643 - Drug Profile
    • LY-900018 - Drug Profile
    • pasireotide - Drug Profile
    • PRL-2903 - Drug Profile
    • Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
    • Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
    • Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
    • terbutaline sulphate MR - Drug Profile
    • XOMA-129 - Drug Profile
    • XOMA-358 - Drug Profile
  • Hypoglycemia - Dormant Projects
  • Hypoglycemia - Discontinued Products
  • Hypoglycemia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypoglycemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hypoglycemia - Pipeline by Adocia SAS, H2 2017
  • Hypoglycemia - Pipeline by Arecor Ltd, H2 2017
  • Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017
  • Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2017
  • Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
  • Hypoglycemia - Pipeline by Novartis AG, H2 2017
  • Hypoglycemia - Pipeline by Therakind Ltd, H2 2017
  • Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2017
  • Hypoglycemia - Pipeline by Vectura Group Plc, H2 2017
  • Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2017
  • Hypoglycemia - Pipeline by XOMA Corp, H2 2017
  • Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2017
  • Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2017
  • Hypoglycemia - Dormant Projects, H2 2017
  • Hypoglycemia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Hypoglycemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top